Our study aimed to address this discrepancy by evaluating the comparative efficacy of tazemetostat, an FDA-approved EZH2 inhibitor, and MS1943, an EZH2 degrader, across diverse lymphoma cell lines. The gene discussed is EZH2; the disease is lymphoma.